<div id="readability-page-1"><p>This year, sales of Bristol Myers Squibb’s (BMS) and Pfizer’s drug Eliquis (apixaban) are projected to decline by 15.2% due to the loss of its European market exclusivity on 19 May 2026. The BMS-Pfizer alliance has dominated the anticoagulant drug market, earning approximately $82.6bn in revenue since 2011, according to GlobalData’s Sales and Forecast Database. However, with the expiry date fast approaching, the loss of Eliquis’ exclusivity will inevitably mark the beginning<br/>of a major patent cliff.</p>    <p>Eliquis first entered the European market in May 2011, following MHRA approvals for various thromboembolic diseases, revolutionising thromboprophylaxis. The second-generation direct oral anticoagulant (DOAC) Eliquis prevents clot<br/>formation through the direct and reversible inhibition of free and clot-bound factor Xa, a key enzyme in the clotting cascade. Unlike traditional anticoagulants, DOACs have significantly higher safety profiles, with the reduced need for monitoring, setting them apart from traditional anticoagulants such as warfarin. Such factors have led to its takeover as a first-line treatment or prophylaxis of various cardiovascular diseases, including pulmonary embolism and non-valvular atrial fibrillation.</p>                                           </div>

IBBQ

<p>Eliquis (apixaban) sales are expected to decline by 15.2% this year as its European market exclusivity expires in May 2026. The drug, developed by Bristol Myers Squibb and Pfizer, has generated approximately $82.6 billion in revenue since its launch in 2011. The impending patent expiry signals a significant shift in the anticoagulant market, as Eliquis has been a leading treatment for various cardiovascular conditions due to its safety profile and ease of use compared to traditional anticoagulants.</p>

- Bristol Myers Squibb’s and Pfizer’s drug Eliquis is expected to see a 15.2% decline in sales this year due to the loss of European market exclusivity on May 19, 2026.  
- Eliquis has generated approximately $82.6 billion in revenue since its 2011 launch, revolutionizing thromboprophylaxis with its superior safety profile compared to traditional anticoagulants like warfarin.  
- The expiration of its exclusivity indicates the onset of a significant patent cliff, impacting its market performance in the anticoagulant sector.

Pharmaceutical Technology

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

Pfizer

Bristol Myers Squibb

Proshares Ultra Nasdaq Biotech

ProShares Ultra Health Care ETF

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

iShares US Pharma

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

iShares Biotechnology ETF

VanEck Biotech ETF

ALPS Medical Breakthrough

Direxion Pharma & Medical Bull 3X

VG Health

The beginning of the end: Eliquis sales forecast to plummet as EU patent expiry nears